Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2018; 9(24):4627-4634. doi:10.7150/jca.28458 This issue Cite

Review

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer

Mao Shang1,2, Chunxiao Chang 3, Yanqing Pei4, Yin Guan5, Jin Chang6, HuiHui Li3✉

1. School of Medicine and Life Sciences, University of Jinan Shandong Academy of Medical Sciences, Jinan, Shandong, China
2. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 250117
3. Department of Medical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 250117
4. Department of Quality Management Office, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 250117
5. Department of Medical Oncology, Beijing Chao-Yang Hospital, Beijing, China.
6. Oncology department, Affiliated Hospital of Taishan Medical university.

✉ Corresponding author: Huihui Li, MD, PhD, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, 440, Jinyan Road, Jinan, Shandong, China. Tel: 15553103209; Email address: More

Citation:
Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J Cancer 2018; 9(24):4627-4634. doi:10.7150/jca.28458. https://www.jcancer.org/v09p4627.htm
Other styles

File import instruction

Abstract

As a specific subtype of breast cancer, Triple-negative breast cancer (TNBC) is associated with worse prognosis and higher tumor aggressiveness than HER2-amplified or hormone receptor positive breast cancers. Circulating tumor DNA (ctDNA), as a non-invasive “liquid biopsy”, is an emerging original blood-based biomarker for early breast cancer diagnosis, monitoring treatment response, and determining prognosis. In TNBC patients, ctDNA has an inherent tendency to characterize tumor heterogeneity and metastasis-specific mutations providing a key alternative to tumor tissue profiling. Several studies have already demonstrated the potential of ctDNA in TNBC patients from early to advanced stages of the disease including diagnosis, therapy decisions and assessment of prognosis. This review provides a critical brief summary of the evidence that gives credence to the utility of ctDNA as a biomarker for its role into clinical management in TNBC.

Keywords: triple-negative breast cancer, circulating tumor DNA, liquid biopsy

Citation styles

APA
Shang, M., Chang, C., Pei, Y., Guan, Y., Chang, J., Li, H. (2018). Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. Journal of Cancer, 9(24), 4627-4634. https://doi.org/10.7150/jca.28458.

ACS
Shang, M.; Chang, C.; Pei, Y.; Guan, Y.; Chang, J.; Li, H. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J. Cancer 2018, 9 (24), 4627-4634. DOI: 10.7150/jca.28458.

NLM
Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J Cancer 2018; 9(24):4627-4634. doi:10.7150/jca.28458. https://www.jcancer.org/v09p4627.htm

CSE
Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. 2018. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J Cancer. 9(24):4627-4634.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use